gsk598809
Small moleculeexperimental
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00437632)
Timeline
Indications
Mechanism of action
- Dopamine D3 receptorINHIBITOR
DRD3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk598809
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01188967 | Phase 2 | Aug 1, 2010 | GlaxoSmithKline, Harvard University, Mclean Hospital, National Institute on Drug Abuse (NIDA) |
| NCT00908206 | Phase 1 | May 1, 2009 | GlaxoSmithKline |
| NCT00793468 | Phase 2 | Dec 1, 2008 | GlaxoSmithKline |
| NCT01039454 | Phase 1 | Dec 1, 2008 | GlaxoSmithKline |
| NCT00887367 | Phase 1 | Sep 1, 2008 | GlaxoSmithKline |
| NCT00728897 | Phase 1 | Jul 1, 2008 | GlaxoSmithKline |
| NCT00728052 | Phase 1 | Jun 1, 2008 | GlaxoSmithKline |
| NCT00605241 | Phase 1 | Feb 1, 2008 | GlaxoSmithKline |
| NCT00468806 | Phase 1 | Apr 1, 2007 | GlaxoSmithKline |
| NCT00437632 | Phase 1 | Mar 1, 2007 | GlaxoSmithKline |
| NCT00437840 | Phase 1 | Mar 1, 2007 | GlaxoSmithKline |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 11 | 10 | 2 | 2007 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Mclean Hospital | Academic/Hospital | 1 | 0 | 1 | 2010 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1